PHILADELPHIA, Feb. 11, 2008 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that it has accepted an invitation to present at the 10th Annual BIO CEO & Investor Conference, February 11-13, 2008, at the Waldorf Astoria Hotel in New York City. Hemispherx's President and Chief Operating Officer, Anthony Bonelli, will address analysts, institutional portfolio managers and other investors at 11:00 AM, February 13th, in the Waldorf Astoria's Duke of Windsor Room. A live webcast of the presentation can be accessed on the Company's website: www.hemispherx.net. An archive of this presentation will be available for 30 days.
More than 300 biotechnology companies are scheduled to present at the conference, with more than 2,500 analysts and investors in attendance. Mr. Bonelli's remarks will focus on the Company's progress in bringing its lead drug compound, Ampligen(r), an experimental therapeutic, to commercial fruition against Chronic Fatigue Syndrome ("CFS"), as well as opportunities for Ampligen(r) to enhance both preventative and therapeutic vaccines against a variety of indications, including seasonal and pandemic influenza, HIV, cancer and other infectious diseases.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(r) and Oragens(r). Ampligen(r) and Oragens(r) represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 100 patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(r)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States. For more information please visit http://www.hemispherx.net.
About BIO CEO & Investor Conference
BIO CEO & Investor Conference is in its tenth year, having grown to be the largest independent investor conference focused on publicly-traded biotechnology companies. Each year the Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, presentations by more than 300 biotechnology companies, one-on-one meetings, and networking opportunities. Major sponsors of the 2008 event include Pacific Growth Equities, Jeffries Group, Inc., Rodman & Renshaw, Collins Stewart, Natixis Bleichroeder , Stanford Financial Group, Abbott Laboratories, Johnson & Johnson, Pfizer, Ernst & Young, Merck, American Association for Cancer Research, Bench International, BIO IB, biomed tracker, BMO Capital Markets, Business Wire, Foley Hoag LLP, Gerson Lehman Group, Heller Ehrman LLP, Italian Trade Commission, Novozymes, NYSE Euronext, Price Waterhouse Coopers, and VWR. The event website can be found at www.ceo.bio.org.
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(r), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(r) do not imply that the product will ever be specifically approved commercially for these other treatment indications.